We support a diverse pipeline of clinical and translational research that addresses key clinical questions while deepening our understanding of cancer biology, to find better ways to prevent, detect and treat it.
We aim to maximise patient benefit by funding research across the clinical and translational pipeline, including early phase and first-in-human trials, ambitious and innovative trial design, and clinical infrastructure. We're also committed to ensuring that clinical scientists have the support they need to develop a career in clinical research and have a range of opportunities available for researchers at all career stages.
Our single, modular-based funding scheme supports these ambitions by funding high-quality clinical research and associated translational research, as well as the collection of samples and data.
We set out our more detail on our priorities and how we intend to achieve them in our clinical research statement of intent, which is used as a basis for strategic discussion by the Clinical Research Committee.
Explore our fundingRead our clinical research statement of intentOur Clinical Research Committee oversees our funding and endorsement of investigator-led clinical trials and other research supporting or enabling clinical trials.
Find out more about the committee
The committee works with expert review panels, as well as patient and public panels to support research with potential to make a practical impact on clinical practice or policy.
You can find out who we have recently funded for a taste of the kinds of projects we support.
Explore our recently funded awards
Our seven CTUs help investigators design, conduct, analyse and publish clinical trials of all phases that impact the care and outcomes for cancer patients in the UK and around the world.
The ECMC network of 17 adult and 12 paediatric centres supports early-phase clinical trials and translational research to develop the cancer drugs of the future.
Our 15 senior research nurses facilitate the delivery of high-quality clinical trials and are a key interface between researchers, health professionals and people affected by cancer.
The CDD provides expertise and facilities to turn promising research ideas into novel therapeutics, imaging agents, cell therapies, vaccines and targeted small molecules.
Richard Mair, Juanita Lopez and Nader Sanai talk about the 5G trial - a first-of-its-kind precision adaptive platform trial for glioblastoma. testing existing therapies which have proven safe and effective in other cancers.
Yemi Akali talks about the benefits and challenges of decentralised clinical trials and explores where the opportunities lie for cancer trials.
Graham Cadwallader, Head of Clinical Funding, shares about the bold changes we are making to the way we fund clinical research.
We have a variety of fellowships, bursaries and other career development opportunities for academic and clinician researchers, whether you're new to the lab or looking for funding to start your independent research group.
Explore our research career development opportunities
We invest in creative people who can deliver research of the highest quality. Our strategy shapes how we'll discover more about how cancer develops and progresses to unlock new and better ways to prevent, detect and treat it.
We're committed to ensuring our trials are registered and the results reported so researchers can gain the greatest possible insight from data generated and maximise the benefit for people affected by cancer. As part of this, we monitor registration and reporting compliance and publish the results annually.
We host scientific conferences, workshops, webinars and other events. Join us to hear about the latest science, present your research and network with our exceptional community.
Subscribe to our newsletters to hear about the latest news, funding opportunities, events and conferences and other research stories.
